Tofacitinib en el tratamiento de la colitis ulcerosa: casos clínicos / Tofacitinib for the treatment of ulcerative colitis: report of two cases
Rev. méd. Chile
;
148(7): 1039-1043, jul. 2020. graf
Artículo
en Español
| LILACS
| ID: biblio-1139408
RESUMEN
Biological therapy dramatically changed the management of Ulcerative Colitis (UC). However, a significant number of these patients fail to respond or have secondary loss of response to this strategy. In this clinical situation, the options include intensification of anti-TNF therapy, the use of a second anti-TNF or being switched to another drug class. Among the later, tofacitinib, an oral small molecule directed against the JAK/STAT pathway, is safe and effective in inducing and maintaining remission in patients with moderate-severe UC. We report two patients with UC refractory to conventional treatment and biological therapy, who responded successfully to the use of tofacitinib.
Texto completo:
Disponible
Índice:
LILACS (Américas)
Asunto principal:
Piperidinas
/
Pirimidinas
/
Colitis Ulcerosa
/
Inhibidores de Proteínas Quinasas
Límite:
Humanos
/
Masculino
Idioma:
Español
Revista:
Rev. méd. Chile
Asunto de la revista:
Medicina
Año:
2020
Tipo del documento:
Artículo
País de afiliación:
Chile
Institución/País de afiliación:
Clínica Las Condes/CL
/
Facultad de Medicina Universidad/CL
Similares
MEDLINE
...
LILACS
LIS